JD-5037 is a potent CB1R antagonist with an IC50 of 1.5 nM.

Product information

CAS Number: 1392116-14-1

Molecular Weight: 572.51

Formula: C27H27Cl2N5O3S

Chemical Name: (2S)-2-{[(1E)-[(4-chlorobenzenesulfonyl)imino][(4S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]methyl]amino}-3-methylbutanamide

Smiles: CC(C)[C@H](N/C(=N\S(=O)(=O)C1=CC=C(Cl)C=C1)/N1C[C@H](C2=CC=CC=C2)C(=N1)C1C=CC(Cl)=CC=1)C(N)=O

InChiKey: GTCSIQFTNPTSLO-RPWUZVMVSA-N

InChi: InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)/t23-,24+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 100 mg/mL (174.67 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice.

Products are for research use only. Not for human use.